Hemispherx BioPharma (HEB) Stock: Gaining On Clinical Update


Hemispherx BioPharma, Inc (NYSEMKT: HEB) is having an incredibly strong day in the market today, and for good reason. The company recently announced an update with regard to a key clinical development. Of course, this led to excitement among investors who are sending the stock toward the sky. As is usually the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:07), HEB is trading at $0.60 per share after a gain of $0.09 per share (18.61%) thus far today.

HEB Gains On Clinical Developments

As mentioned above, Hemispherx is having an incredibly strong day in the market today after announcing a clinical update. In a press release, the company said that 12 pediatric patients are undergoing treatment with single-agent Ampligen immuno-oncology therapy. The treatments are taking place in what is known as an Early Access Program, or simply EAP. This program is being managed by an Amsterdam-based company known as myTomorrows, which is an international leader in providing physician access to experimental medications.

According to the press release offered by HEB, 8 of the 12 patients entered into the program with metastatic disease in late stage and have been on the treatment for 12 weeks or longer. The four other patients included in the study entered the program in the last several weeks with earlier stage disease.

In a statement, Thomas K. Equels, CEO at HEB, had the following to offer:

Ampligen has been shown in numerous earlier studies to possess both tumor-killing an immuno-modulating activlity, the two characteristics that form the basis of immuno-oncology therapy. This is developing into one of the fastest growing and promising forms of cancer treatment… The program at Erasmus is intended to see if Ampligen’s immuno-modulating properties correlate to disease progression and increased survival of pancreatic cancer patients who have run out of conventional therapeutic options. We are very pleased with the progress so far. As evidenced in our many prior clinical studies, Apligen appears to be generally well-tolerated by the pancreatic patients in this program.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HEB. In particular, we’re interested in following the ongoing work surrounding Ampligen, as the treatment seems to be promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here